Top Ranked TSX Venture-Listed LP Eyes 32-Acre Expansion — CFN Media

SEATTLE, WA–(Marketwired – Mar 8, 2017) – CFN Media Group (“CFN Media”), the leading agency and digital media network dedicated to legal cannabis, today announced publication of an article covering Emerald Health Therapeutics Inc.’s (TSX VENTURE: EMH) recent performance ranking from the Venture exchange as well as the progress being made on its aggressive expansion plans.

Emerald Health is ranked third in the Clean Technology & Life Sciences sector of the 2017 TSX Venture 50 based on its market capitalization growth, share price appreciation, and trading volume. Last year, the stock price jumped nearly 500% from a low of 15 cents to over C$1.25. On February 23, the company was also featured in a video profile and official announcement of the top-ranking stocks in each sector.

Emerald Health is one of less than 40 licensed producers under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). According to Deloitte, the country’s cannabis sector could be worth more than $22.6 billion following the legalization of recreational marijuana. The lack of supplies to the large and growing market could create a shortfall over the coming years, particularly as the country begins exporting product around the world.

The company is well underway with its first phase of expansion that will add 50,000 square feet of cultivation space and a state-of-the-art facility with anticipated capacity in excess of 5,000 kilograms per year. In its second phase, the company will scale-up in a modular fashion with 50,000 additional square feet in the near-term. Management anticipates that both phases will be completed in 2018 with sales commencing when licensing is completed.

The company has the capacity to build out an aggregate one million square feet of total production space on its 32-acre Metro Vancouver property.

At the same time, the company continues to expand its genetic portfolio and develop its clinical programs. The staff is in the process of characterizing unique strains with high and desirable ratios of therapeutic cannabinoids while assembling a proven cultivation team to ultimately bring them to market. The company is also collaborating with leading physicians and researchers to design clinical studies to demonstrate the efficacy of its own products.

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed. 

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

CFN Media
Frank Lane
[email protected]